Paul Sakuma, Associated Press
SALT LAKE CITY — Utah will get $8.5 million from GlaxoSmithKline for defrauding the state’s Medicaid program through allegedly false and misleading marketing of Avandia.
GSK introduced Avandia in 1999 as a new diabetic medication to treat Type 2 diabetes by helping sensitize cells to insulin and thereby assisting in blood-sugar control.
The Medicaid Fraud Control Unit of the attorney general’s office filed the lawsuit in 2010 and alleged GSK marketed Avandia nationwide as a “wonder drug” and as a “significant advance” in diabetes treatment.
The lawsuit also alleged Avandia has been proven to increase the risk of cardiovascular events, including heart attacks, among certain users of Avandia.
“This settlement is a great outcome in a complex case,” said Robert Steed, director of the Medicaid fraud unit.
— Dennis Romboy
- Summer downpour causes flooding, slides...
- Swallow, Shurtleff make first court...
- Utah leads the nation in deadly melanoma cases
- Project to restore Manti Tabernacle underway
- Provo's waffle truck started by a motivated...
- Video of school bus driver shows 'bizarre'...
- Settlement in dog shooting case reached, then...
- Cartel presence in Utah 'exploding' with...
- Republican, Democratic political... 37
- Ex-federal judge says West Valley... 25
- Owens' pollster says new poll shows... 22
- Drunken driver goes airborne, crashes... 21
- Swallow, Shurtleff make first court... 20
- Provo's waffle truck started by a... 19
- Critics decry solar fee as 'sun' tax 17
- Long road to trial begins Wednesday for... 13